کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3997694 1259168 2016 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Is there a justification for hysterectomy in patients with borderline ovarian tumors?
ترجمه فارسی عنوان
آیا توجیه برای هیسترکتومی در بیماران با تومورهای مرزی تخمدان وجود دارد؟
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
چکیده انگلیسی


• We aimed to determine the frequency of uterine involvement in patients with BOT.
• We evaluated the recurrence risk and survival after hysterectomy.
• Fertility-sparing surgery was associated with more recurrent BOT.
• Fertility-sparing surgery was associated with more ovarian invasive disease.
• Hysterectomy affected favorably borderline disease-free survival.

ObjectiveTo determine the frequency of uterine involvement in patients with borderline ovarian tumors (BOT) and to evaluate the recurrence risk and survival after hysterectomy.Materials and methodsIn two French hospitals: A tertiary referral centre (University hospital centre of Tours, France) and the Alliance community hospital of Tours (France), we reviewed data of consecutive women undergoing surgery for presumed stage I BOT between January 1997 and December 2012. Patients were divided into two groups: patients treated with fertility sparing surgery (group 1) and those treated with radical surgery (group 2).ResultsA total of 135 patients were evaluated. 35 had fertility sparing surgery, 81 had radical surgery with hysterectomy and 19 had previous hysterectomy for other reasons. There were more recurrent borderline ovarian disease and more ovarian invasive disease developed in group 1 (p = 0.02, p = 0.04, respectively). Hysterectomy affected favorably borderline disease-free survival, OR = 0.09 95%CI (0.005–0.69), p = 0.04, but perceived benefits may be related to bilateral salpingo-oophorectomy and not hysterectomy directly.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Surgical Oncology - Volume 25, Issue 1, March 2016, Pages 1–5
نویسندگان
, , , , , , , ,